Deadly Allergy

Investigating causes and cures of anaphylaxis

  • News
  • Science
  • Resources
    • Airborne / Contact Allergy
    • They know …..
  • History
  • Treatments
  • PENTA Project
  • Contact Us

PENTA Project

Parents of children affected by food anaphylaxis and/or autism have spent numerous years and countless hours investigating why our children are affected with such severe immune system and brain malfunctions. The PENTA Project investigations have revealed that the PENTA 5 in 1 combination (1994 – 1997) did not have a DIN # or a Notice of Compliance rendering it illegal according to Health Canada. 11,000+ adverse events, including deaths, were reported to PHAC for the PENTA combination over the three years that PENTA was in use.   You may request PHAC ATIP reports A-2013-00096 and A-2013-00097 to view all of this data, which is too large to upload to a website. All subsequent 5 in 1 vaccines including Pentacel and Pediacel are based on this illegal combination, putting into question all vaccine schedules since 1994.

Access to Information requests over many years to all levels of government including requesting PENTA licensing information provided scant information, and Ontario, Canada, and local health unit ATIP responses did not acknowledge that the PENTA combination existed at all!

The Biologics and Genetic Therapies Directorate at Health Canada admits in this e-mail that “As a result the Penta vaccine does not have an associated DIN of its own” which renders it illegal in Canada.

PENTA Vaccine Letter to the Canadian and Ontario Health Ministers (2016) (pdf)

Vaccine Adverse Events reported for my child’s PENTA vaccine (DPT-Polio + Hib) lot # totalled 670 and it was never pulled from the market.

A University of Saskatchewan information sheet (2004) stated, “Significant side effects were observed after PENTA vaccination, commonly blamed on the whole cell pertussis component. PENTA was also only about 60–80% effective against pertussis.”  

Only one study for the PENTA combination was referenced by Canada’s National Advisory Committee on Immunization in their Supplementary statement on newly licensed Haemophilus influenzae type B (Hib) conjugate vaccines in combination with other vaccines recommended for infants. That study, Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age (pdf) was funded by the vaccine manufacturer, Connaught Laboratories Ltd. There are lots of concerns in this article. Infants were followed for 48 hours, but “Nurses were authorized to extend follow-up for 7 to 10 days by telephone or home visit if severe adverse events occurred.” 440 infants were enrolled, all receiving 5 vaccines in one injection or separate injections.   It is terrifying to think that the following was considered as justification to give babies five vaccinations at once:

“Thirteen infants were withdrawn from the study: … “1 because of maternal request following adverse symptoms after dose 2; 1 because of physician request after unconsolable crying following dose 1; 1 because of developmental delay with onset unrelated temporally to vaccination ; and 3 after severe adverse events leading to hospitalization within 48 hours of vaccination.”

“Three severe adverse events temporally associated with vaccination resulted in hospitalization; (1) an infant (Group C2) developed supraventricular tachycardia 48 hours after Dose 1 which responded promptly to digoxin therapy; (2) an infant (Group S1) was hospitalized after waking 3 hours after Dose 1 with cough, respiratory distress and cyanosis. Recovery occurred within 4 hours. Aspiration or gastro-esophageal reflux was suspected; (3) an infant (Group S2) was hospitalized after an episode of screaming with apnea or breath-holding 4 hours after Dose 1.”

“The causes of the interactions among antigens in both the quadrivalent and pentavalent vaccines are not known. The hypothesis that the tetanus toxoid conjugate is involved in producing the interactions is supported by the lack of such interactions after vaccination with combined DPT H. influenzae-CRM conjugate (Hb)C vaccines.”

“The clinical relevance of the reduced antibody concentrations in relation to protection against disease is unknown.”

 

Archive of the Penta Project website

The reality of vaccine injury: a much needed lesson for Carly Weeks – February 2019

 

In Memory of Pierre Morin, Penta vaccine parent, who passed away in October, 2010. 

 

Penta Vaccine – Canada’s first 5 in 1 Pentavalent vaccination given from 1994 – 1997.

Search This Site

Pages

  • News
  • Science
  • Resources
    • Airborne / Contact Allergy
    • They know …..
  • History
  • Treatments
  • PENTA Project
  • Contact Us

Recent Posts

  • COVID-19 UK Advises People With Serious Allergies To Avoid Pfizer COVID-19 Vaccine – Canada issues advisory
  • CBC Ignores Vaccine Science
  • Vaccines contain food proteins
  • Influenza allergy?
  • What about peanut oil in vaccines?
  • PENTA Vaccine Letter
  • PENTA Cover-Up at CBC
  • Vaccines cause the development of food allergies: the latest evidence

Twitter

Follow @vaccinerisk

Pages

  • News
  • Science
  • Resources
    • Airborne / Contact Allergy
    • They know …..
  • History
  • Treatments
  • PENTA Project
  • Contact Us

Archives

  • December 2020
  • February 2020
  • April 2018
  • March 2018
  • December 2016
  • October 2016
  • July 2016

Categories

  • News (2)
  • PENTA Project (2)
  • Resources (1)
  • Uncategorized (3)

WordPress

  • Log in
  • WordPress
© A WordPress Site
  • News
  • Science
  • Resources
  • History
  • Treatments
  • PENTA Project
  • Contact Us
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}